Figure 6.

Distribution of local tolerability assessment scores among patients for (a) erythema, (b) dryness, (c) peeling, (d) itching and (e) burning/stinging (ITT population). ADA, adapalene; BPO, benzoyl peroxide; CLNP, clindamycin phosphate; ITT, intent‐to‐treat.